Advancing Healthcare Energy: Olympus Awarded PROVISTA Contract

Provista

Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the POWERSEAL™ sealer/divider, the SONICBEAT™ ultrasonic portfolio and THUNDERBEAT™ hybrid energy portfolio.

The multi-year agreement was effective as of July 1, 2023.

The Olympus advanced energy portfolio is available under this contract, including:

  • The Universal Surgical Energy Generator (EPF-1), which provides common forms of surgical energy and eliminates the need for multiple generators.
  • The SONICBEAT Ultrasonic Energy Portfolio, which offers precise dissection with 5mm sealing and secure tissue grasping thanks to unique wiper jaw design.1
  • The THUNDERBEAT Hybrid Energy Portfolio, which offers efficiency through fast cutting and versatility and 7mm sealing and precise dissection.2
  • The POWERSEAL Sealer/Divider, which features a curved, tapered and double-action Maryland dissector/grasper design and vessel sealing up to and including 7mm, including pulmonary vessels, tissue bundles and lymphatics.3

Jay Sullivan, Group Vice President, Enterprise Solutions, Medical Systems Group, Olympus

“Contract awards are important to our business. But even more important is that the Provista awards create opportunities for customers such as ASCs to access state-of-the-art equipment toward improving patient care in a value-based framework. The ASC market is important for healthcare providers and the communities they serve, and we are focused on growing our presence there.”

Energy Options Offered Through Olympus

Olympus offers an array of energy options such as the THUNDERBEAT hybrid energy devices portfolio that deliver ultrasonic and bipolar energy simultaneously for tissue management, including hemostatic cutting and dissection, in laparoscopic surgery and open surgery. Olympus’ POWERSEAL devices can be used in general surgery and gynecological, colorectal, bariatric, urological, thoracic and vascular surgical procedures.

EPF-1 Generator

The EPF-1 generator, with its accessories and ancillary equipment, is intended for cutting and coagulation of tissue in open, laparoscopic and endoscopic surgery and should only be used by a qualified physician in an adequate medical environment.  Improper use or use of incompatible equipment with these generators may lead to excessive or incorrect HF and cause thermal or other injuries for the patient and/or operator.

All plugs must be securely inserted into the corresponding sockets for proper use. Be aware that if the main plug is accidentally disconnected during a procedure, the electrosurgical generator immediately turns off and this may result in complications for the patient should it occur during energy delivery. Please refer to the instructions for use prior to usage.

References

1 Data on file with Olympus (869-2368, 869-2512)
2 Data on file with Olympus (868-4375, 868-4378, 868-3710)
3 Data on file with Olympus (DN004705, DN0044706)

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.